News of the company Amorfix Life Sciences

Article 1 to 6 out of 6 concerning Amorfix Life Sciences Ltd.

Amorfix achieves target sensitivity with its Alzheimer's disease diagnostic test (26 Jun 2008)
Amorfix Life Sciences announced that its diagnostic test for the presence of aggregated Abeta in Alzheimer's disease is ready to be applied to patient samples. The company has adapted its test to specifically detect aggregated Abeta protein ...

more information
�
Amorfix detects scrapie prions in blood from asymptomatic sheep (05 May 2008)
Amorfix Life Sciences Ltd. announced the detection of endogenous prions in the blood plasma of asymptomatic scrapie infected sheep. The company had previously reported detecting symptomatic sheep which was a requirement for testing of human vCJD in ...

more information
�
Amorfix achieves technical milestone in development of a blood test for Alzheimer's disease (07 Sep 2006)
Amorfix Life Sciences Inc. and the Ontario Genomics Institute (OGI) announced the achievement of the technical milestone of demonstrating that Amorfix's Epitope Protection (EP) technology is able to detect protected sites within Abeta amyloid ...

more information
�
Amorfix announces leading sensitivity for prion detection in spiked human blood samples (23 Jun 2006)
Amorfix Life Sciences Ltd. announced it had completed the analysis of the international reference blinded panels of human blood samples spiked with prions from variant Creutzfeldt-Jakob Disease (vCJD) patients which were provided by the UK ...

more information
�
Amorfix and Ontario Genomics Institute announce partnership to accelerate development of blood test for Alzheimer's Disease (02 Feb 2006)
Amorfix Life Sciences Inc. and the Ontario Genomics Institute (OGI) announced they are entering into a partnership to develop a blood test for Alzheimer's disease, EP-AD(TM), based upon Amorfix's patent-pending Epitope Protection technology. OGI ...

more information
�
Amorfix Life Sciences Ltd. reports identification of epitopes on bovine prion protein and approval of laboratory for BSE samples (30 Jan 2006)
Amorfix Life Sciences Ltd. reported that it has completed the first step towards adapting its patent pending Epitope Protection technology to detecting bovine prions, the infectious aggregated misfolded proteins that cause BSE. This advance was ...

more information
�

Current NewsRSS

my.analytica-world.com

Current News RSS